Amendment to Schedule 13G Filing for Nektar Therapeutics by Integrated Core Strategies (US) LLC and Others

Integrated Core Strategies (US) LLC, Millennium Management LLC, Millennium Group Management LLC, and Israel A. Englander have filed an amendment to their Schedule 13G for Nektar Therapeutics. The filing indicates that these entities collectively own 3.0% of Nektar Therapeutics' common stock. The amendment, filed under Rule 13d-1(c), confirms that the securities were not acquired for the purpose of influencing the control of the issuer. The filing includes a joint filing agreement dated October 27, 2025, and is signed by Gil Raviv, Global General Counsel, and Israel A. Englander.